Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
Tatsuhiro Shibata(National Cancer Research Institute), Naoya Yamazaki
Cited by 130
Related Papers
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
|Hepatology|2013|554
Genetic Alteration of Keap1 Confers Constitutive Nrf2 Activation and Resistance to Chemotherapy in Gallbladder Cancer
|Gastroenterology|2008|471
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
|British Journal of Cancer|2011|127
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
|British Journal of Cancer|2009|95
Integrated genetic and epigenetic analysis of myxofibrosarcoma
|Nature Communications|2018|85